An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer.

被引：2
|
作者：
Moehler, M. H.
Hartmann, J. T.
Lordick, F.
Al-Batran, S.
Reimer, P.
Trarbach, T.
Ebert, M. P.
Daum, S.
Weihrauch, M.
Galle, P. R.
机构：
[1] Johannes Gutenberg Univ Mainz, D-55122 Mainz, Germany
[2] Christian Albrechts Univ Kiel Klinikum, Kiel, Germany
[3] Klinikum Braunschweig, Med Dept 3, Braunschweig, Germany
[4] Krankenhaus NW Frankfurt, Frankfurt, Germany
[5] Kliniken Essen Sued, Essen, Germany
[6] Univ Duisburg Essen, Dept Med, West German Canc Ctr, Essen, Germany
[7] Tech Univ Munich, Klinikum Rechts Isar, Med Dept 2, D-80290 Munich, Germany
[8] Charite, Berlin, Germany
[9] Univ Cologne, Dept Internal Med 1, D-50931 Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e14503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14503
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.
    Abu-Khalaf, Maysa M.
    Mayer, Ingrid A.
    Tankersley, Chris
    Moy, Jadine
    Allen, Andrew R.
    Vogel, Charles L.
    Holmes, Frankie Ann
    Nanda, Rita
    Miller, Kathy
    Patel, Ravindranath
    Pusztai, Lajos
    Arteaga, Carlos L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] A prospective, open-label, multicenter, phase IV clinical study on the safety and efficacy of lobaplatin in the treatment of metastatic breast cancer.
    Xu, Binghe
    Yan, Min
    Ouyang, Quchang
    Han, Guohui
    Cheng, Ying
    Wang, Dewei
    Li, Ran
    Zhao, Da
    Sun, Tao
    Bai, Yuju
    Yu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Oxaliplatin and Irinotecan in advanced gastric cancer.: A multicenter phase II trial
    Woell, E.
    Eisterer, W.
    Hilbe, W.
    Kuehr, T.
    Gattringer, K.
    Greil, R.
    Zabernigg, A.
    Baldinger, C.
    Thaler, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 213 - 213
  • [34] Intragastric Injection of Botulinum Toxin a to Treat Gastric Cancer: An Open-Label Phase II Clinical Trial
    Andersen, Goran
    Zhao, Chun-Mei
    Cai, Xing
    Rabben, Hanne-Line
    Fox, James G.
    Wang, Timothy C.
    Chen, Duan
    Gronbech, Jon Erik
    GASTROENTEROLOGY, 2016, 150 (04) : S1251 - S1252
  • [35] An open-label phase II trial to assess to efficacy of sunitinib as an antieffusion agent in patients with malignant peritoneal and/or pleural effusions
    Trinh, X.
    van Dam, P.
    Tjalma, W.
    Wojtasik, A.
    Lybaert, W.
    Rasschaert, M.
    Rutten, A.
    Prove, A.
    Vermeulen, P.
    Dirix, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer.
    Fields, ALA
    Rinaldi, DA
    Henderson, CA
    Germond, CJ
    Chu, L
    Brill, KJ
    Leopold, LH
    Berger, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 266S - 266S
  • [37] A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer(RADIT)
    Fenner, Martin H.
    Dieing, Annetta
    Oechsle, Karin
    Hentrich, Marcus
    Gauler, Thomas Christoph
    Lorch, Anja
    Kopp, Hans-Georg
    Beyer, Joerg
    Bokemeyer, Carsten
    Gruenwald, Viktor
    Honecker, Friedmann
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
    Carlos R. Becerra
    Ramon Salazar
    Rocio Garcia-Carbonero
    Anne L. Thomas
    Federico J. Vázquez-Mazón
    James Cassidy
    Tim Maughan
    Manuel Gallén Castillo
    Tim Iveson
    Donghua Yin
    Stephanie Green
    Emily K. Bergsland
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 695 - 702
  • [39] A phase 3 open-label, randomized, multicenter study of imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer.
    Huhn, Richard Dale
    Lowe, Jamie
    Grady, Michele M.
    Taitt, Corina Candiani
    Braun, Ada H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
    Becerra, Carlos R.
    Salazar, Ramon
    Garcia-Carbonero, Rocio
    Thomas, Anne L.
    Vazquez-Mazon, Federico J.
    Cassidy, James
    Maughan, Tim
    Gallen Castillo, Manuel
    Iveson, Tim
    Yin, Donghua
    Green, Stephanie
    Bergsland, Emily K.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 695 - 702
12345